Medscape1mon
FDA OKs First Mesenchymal Stromal Cell Therapy for GVHD
Marcus Center for Cellular Cures at Duke University Medical Center (DUMC), Durham, North Carolina, said in company news release. Ryoncil “will be life saving for so many children and will have a ...
BioSpace1mon
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Transplant physician Dr Joanne Kurtzberg, the Jerome Harris Distinguished Professor of Pediatrics and Professor of Pathology, and Director, Marcus Center for Cellular Cures at Duke University Medical ...
ahajournals.org7y
Endovascular Therapies for Acute Ischemic Stroke in Children
In adult AIS, there is overwhelming evidence to support intravenous (IV) tissue-type plasminogen activator (tPA) within 4.5 hours of symptom onset and mechanical thrombectomy for large vessel ...